CN112409431A - Cytarabine structure analogue and preparation method and application thereof - Google Patents
Cytarabine structure analogue and preparation method and application thereof Download PDFInfo
- Publication number
- CN112409431A CN112409431A CN202011427716.1A CN202011427716A CN112409431A CN 112409431 A CN112409431 A CN 112409431A CN 202011427716 A CN202011427716 A CN 202011427716A CN 112409431 A CN112409431 A CN 112409431A
- Authority
- CN
- China
- Prior art keywords
- cytarabine
- structural
- analogue
- cells
- structural analogue
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical group O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 title claims abstract description 193
- 238000002360 preparation method Methods 0.000 title abstract description 10
- 229960000684 cytarabine Drugs 0.000 claims abstract description 171
- 239000003814 drug Substances 0.000 claims abstract description 48
- 208000032839 leukemia Diseases 0.000 claims abstract description 23
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 51
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 39
- 150000001875 compounds Chemical class 0.000 claims description 36
- 239000000243 solution Substances 0.000 claims description 29
- 238000006243 chemical reaction Methods 0.000 claims description 25
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 20
- 239000000706 filtrate Substances 0.000 claims description 20
- 239000000047 product Substances 0.000 claims description 18
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 claims description 12
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 claims description 10
- 238000004440 column chromatography Methods 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 9
- 238000011282 treatment Methods 0.000 claims description 9
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 8
- 239000012074 organic phase Substances 0.000 claims description 8
- DLYUQMMRRRQYAE-UHFFFAOYSA-N phosphorus pentoxide Inorganic materials O1P(O2)(=O)OP3(=O)OP1(=O)OP2(=O)O3 DLYUQMMRRRQYAE-UHFFFAOYSA-N 0.000 claims description 8
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical class ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 claims description 8
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 8
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 7
- 239000012295 chemical reaction liquid Substances 0.000 claims description 7
- 238000010790 dilution Methods 0.000 claims description 7
- 239000012895 dilution Substances 0.000 claims description 7
- MCTWTZJPVLRJOU-UHFFFAOYSA-N 1-methyl-1H-imidazole Chemical compound CN1C=CN=C1 MCTWTZJPVLRJOU-UHFFFAOYSA-N 0.000 claims description 6
- 150000001509 aspartic acid derivatives Chemical class 0.000 claims description 6
- 238000001035 drying Methods 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 238000003756 stirring Methods 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 5
- 229940126214 compound 3 Drugs 0.000 claims description 5
- 238000001816 cooling Methods 0.000 claims description 5
- 229910052739 hydrogen Inorganic materials 0.000 claims description 5
- 239000001257 hydrogen Substances 0.000 claims description 5
- 239000012071 phase Substances 0.000 claims description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 4
- 238000010438 heat treatment Methods 0.000 claims description 4
- 238000000746 purification Methods 0.000 claims description 4
- 238000004809 thin layer chromatography Methods 0.000 claims description 4
- 238000005406 washing Methods 0.000 claims description 4
- 229940125782 compound 2 Drugs 0.000 claims description 3
- 238000001914 filtration Methods 0.000 claims description 3
- 238000012544 monitoring process Methods 0.000 claims description 3
- 238000010791 quenching Methods 0.000 claims description 2
- 229940079593 drug Drugs 0.000 abstract description 31
- 230000005764 inhibitory process Effects 0.000 abstract description 22
- PCDQPRRSZKQHHS-CCXZUQQUSA-N Cytarabine Triphosphate Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 PCDQPRRSZKQHHS-CCXZUQQUSA-N 0.000 abstract description 15
- 239000002207 metabolite Substances 0.000 abstract description 14
- 210000004369 blood Anatomy 0.000 abstract description 13
- 239000008280 blood Substances 0.000 abstract description 13
- 230000000694 effects Effects 0.000 abstract description 13
- 230000035755 proliferation Effects 0.000 abstract description 13
- 238000001727 in vivo Methods 0.000 abstract description 10
- 239000007924 injection Substances 0.000 abstract description 6
- 238000002347 injection Methods 0.000 abstract description 6
- 231100000331 toxic Toxicity 0.000 abstract description 5
- 230000002588 toxic effect Effects 0.000 abstract description 5
- 206010059866 Drug resistance Diseases 0.000 abstract description 4
- 238000009776 industrial production Methods 0.000 abstract description 3
- 230000000149 penetrating effect Effects 0.000 abstract description 3
- 210000004027 cell Anatomy 0.000 description 81
- KCURWTAZOZXKSJ-JBMRGDGGSA-N 4-amino-1-[(2r,3s,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one;hydron;chloride Chemical compound Cl.O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 KCURWTAZOZXKSJ-JBMRGDGGSA-N 0.000 description 22
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 18
- 238000012360 testing method Methods 0.000 description 17
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 16
- 230000002829 reductive effect Effects 0.000 description 15
- 229920006395 saturated elastomer Polymers 0.000 description 13
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 12
- 238000002474 experimental method Methods 0.000 description 9
- 239000010413 mother solution Substances 0.000 description 9
- 239000006285 cell suspension Substances 0.000 description 8
- 230000012010 growth Effects 0.000 description 8
- 230000003698 anagen phase Effects 0.000 description 7
- 239000011148 porous material Substances 0.000 description 7
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- 241000700159 Rattus Species 0.000 description 6
- 230000004663 cell proliferation Effects 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 6
- 230000009036 growth inhibition Effects 0.000 description 6
- 238000012258 culturing Methods 0.000 description 5
- 239000001963 growth medium Substances 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- -1 (1H) -cytosine ketone Chemical class 0.000 description 4
- 238000005160 1H NMR spectroscopy Methods 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 4
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 4
- 230000000719 anti-leukaemic effect Effects 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 230000000875 corresponding effect Effects 0.000 description 4
- 230000003834 intracellular effect Effects 0.000 description 4
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 230000035699 permeability Effects 0.000 description 4
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 3
- 239000012980 RPMI-1640 medium Substances 0.000 description 3
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 238000004364 calculation method Methods 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 239000012894 fetal calf serum Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 239000003208 petroleum Substances 0.000 description 3
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 229940125904 compound 1 Drugs 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 239000001177 diphosphate Substances 0.000 description 2
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 2
- 235000011180 diphosphates Nutrition 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000035484 reaction time Effects 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 238000012453 sprague-dawley rat model Methods 0.000 description 2
- 229940035893 uracil Drugs 0.000 description 2
- 102000000311 Cytosine Deaminase Human genes 0.000 description 1
- 108010080611 Cytosine Deaminase Proteins 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102100029588 Deoxycytidine kinase Human genes 0.000 description 1
- 108010033174 Deoxycytidine kinase Proteins 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 239000005909 Kieselgur Substances 0.000 description 1
- 102000013901 Nucleoside diphosphate kinase Human genes 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 230000018199 S phase Effects 0.000 description 1
- 101710100179 UMP-CMP kinase Proteins 0.000 description 1
- 101710119674 UMP-CMP kinase 2, mitochondrial Proteins 0.000 description 1
- IERHLVCPSMICTF-CCXZUQQUSA-N [(2r,3s,4s,5r)-5-(4-amino-2-oxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl dihydrogen phosphate Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](COP(O)(O)=O)O1 IERHLVCPSMICTF-CCXZUQQUSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000002681 effect on RNA Effects 0.000 description 1
- 238000000589 high-performance liquid chromatography-mass spectrometry Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Abstract
The invention discloses a cytarabine structure analogue and a preparation method and application thereof. The cytarabine structure analogue P1-P4 synthesized for the first time can inhibit the proliferation of the leukemia cell HL-60, and particularly, compared with Ara-C, the cytarabine structure analogue P4 has stronger inhibition capability on the proliferation of the leukemia cell and stronger cell penetrating capability, the concentration of a medicament entering the cell and the concentration of an active metabolite cytarabine triphosphate generated in the cell are higher, and the bioavailability is higher; can be converted into the parent drug cytarabine in cells, obviously improves the blood concentration of target cells in vivo, and can avoid toxic and side effects and drug resistance caused by large-dose medication; obviously prolongs the half-life period of the cytarabine, maintains effective blood concentration for a longer time, can be orally taken, and can avoid the inconvenience caused by injection. The preparation method is simple and easy to operate, and is suitable for industrial production.
Description
Technical Field
The invention belongs to the field of organic synthesis, and particularly relates to a cytarabine structure analogue, and a preparation method and application thereof.
Background
Cytosine arabinoside (Ara-C) chemical name: 1-beta-D-arabinofuranosyl-4-amino-2 (1H) -cytosine ketone with CAS registry number [147-94-4]The molecular formula is as follows: c9H13N3O5The structural formula is as follows:
cytarabine belongs to pyrimidine antimetabolites and is mainly used for treating Acute Myelogenous Leukemia (AML). Ara-C is converted into arabinoside triphosphate (Ara-CTp) in vivo through three steps to exert an anticancer effect. Firstly, cytarabine monophosphate (Ara-CMp) is formed under the catalysis of intracellular deoxycytidine kinase, and then the cytarabine monophosphate and the cytarabine diphosphate are converted into cytarabine diphosphate (Ara-CDp) and active cytarabine triphosphate (Ara-CTp) through the action of nucleoside diphosphate kinase, wherein the cytarabine triphosphate influences DNA synthesis, inhibits the growth of cells and interferes the proliferation of the cells by inhibiting DNA polymerase; it may also penetrate into the DNA in small amounts, interfering with the replication of the DNA and causing cell death. But has no obvious effect on RNA and protein synthesis, belongs to cell cycle specific drugs acting on S phase, is most sensitive to the effect of cells in S proliferation phase, and also has effect on G1/S and S/G2 conversion phase.
Cytarabine was originally developed by Upjohn in the united states and was marketed in the united states 10 months in 1969, and the time of first registration in the country was 1992. Cytarabine has very high molecular polarity, so that the membrane permeability of small intestine is poor, the oral bioavailability of cytarabine is very low, only 20 percent of the medicine enters blood circulation, and the cytarabine is not taken orally but is taken intravenously. Therefore, the cytarabine sold in the market is mainly an injection (powder injection), and at present, a plurality of manufacturers in China produce cytarabine hydrochloride injection. In addition, the medicine can be deaminated by liver cytosine deaminase to form inactive uracil cytosine arabinoside, t1/2The time is short, only 3-15 minutes, so that the effective blood concentration can be maintained only by adopting continuous intravenous drip administration, and a better effect is obtained. For example, when the composition is used for treating acute myelocytic leukemia, the composition is usually injected or instilled intravenously, and the daily dose is 100-200 mg/m2Or 2-6 mg/Kg, and the dosage is increased from small to large until bone marrow suppression appears after being used for 5-7 days. Stop the medicine for 5 to 7 daysCan be used repeatedly after bone marrow recovery. Clinically, the large-dose cytarabine has better long-term treatment effect than the common dose, but has toxic and side effects on blood, nervous systems and organs, is easy to generate drug resistance, and the survival rate in five years is not obviously improved. The toxic and side effects of the cytarabine are positively correlated with the dosage, and the clinical use of the cytarabine is also limited.
Therefore, there is a need to develop more effective therapeutic agents that can be administered orally and conveniently to the convalescent patient out of hospital.
Disclosure of Invention
In view of the above, the invention provides cytarabine structural analogues and a preparation method and application thereof. The cytarabine structural analogue can inhibit the proliferation of human leukemia cells, and particularly, compared with cytarabine, some cytarabine structural analogues have better permeability, higher bioavailability and longer half-life period for leukemia cells, can be orally administered, and are expected to be used as novel anti-leukemia drugs.
In order to achieve the purpose, the invention adopts the following technical scheme:
in a first aspect of the present invention, cytarabine structural analogs are provided, having the general structural formula (I):
wherein R1 ═ Ph or C18H37,
In particular, the present invention relates to a method for producing,
the cytarabine structural analogue can be a cytarabine structural analogue P1 shown in the following formula (II):
alternatively, the cytarabine structural analog may be a cytarabine structural analog P2 represented by the following formula (iii):
alternatively, the cytarabine structural analog may be a cytarabine structural analog P3 represented by the following formula (iv):
alternatively, the cytarabine structural analog may be a cytarabine structural analog P4 represented by the following formula (V):
in a second aspect of the invention, a method for preparing a cytarabine structural analog is provided.
A preparation method of cytarabine structural analogues comprises the following steps:
dissolving cytarabine and phosphoryl chloride derivatives in anhydrous tetrahydrofuran, N2Cooling to-70-78 ℃ under protection, slowly dripping 1-methylimidazole, stirring at-70-78 ℃, heating to room temperature for reaction, and after the reaction is finished, carrying out post-treatment and purification on reaction liquid to obtain a product; wherein,
when the phosphoryl chloride derivative is a compound 2 shown as the following formula (VI), the obtained product is a cytarabine structure analogue P1;
when the phosphoryl chloride derivative is a compound 4 shown as the following formula (VII), the obtained product is a cytarabine structure analogue P3;
in a preferred embodiment, cytarabine: phosphorus oxychloride derivatives: the molar ratio of 1-methylimidazole is 1: (1.5-2.0): (2.0-3.0).
In the preferred technical scheme, the stirring time is 1-2 hours.
In a preferred technical scheme, the temperature rise is natural temperature rise.
In a preferred technical scheme, the room temperature reaction time is 12-16 hours.
In a preferred technical scheme, the post-treatment purification comprises the following steps: concentrating the reaction solution, adding dichloromethane for dilution, washing with dilute hydrochloric acid, water and saturated sodium chloride solution successively, combining organic phases, drying, concentrating, and purifying by column chromatography to obtain the product.
In a preferred embodiment, the concentration is carried out under reduced pressure, most preferably under reduced pressure at 40 ℃.
In the preferable technical scheme, the column chromatography adopts dichloromethane/methanol with the volume ratio of 20/1-10/1.
Or,
a preparation method of cytarabine structural analogues comprises the following steps:
dissolving the selected compound and aspartic acid derivative in anhydrous tetrahydrofuran, N2Cooling to-5-0 deg.C under protection, slowly dripping 1-propyl phosphoric anhydride, heating to room temperature for reaction, and reacting to obtain the first reaction solution3Quenching the solution, extracting the water phase by using dichloromethane, combining the organic phases, drying, concentrating, and purifying by column chromatography to obtain an intermediate; dissolving the intermediate in methanol, adding Pd/C, introducing hydrogen for reaction, monitoring by thin-layer chromatography, and performing aftertreatment on the obtained second reaction liquid to obtain a product; wherein,
the aspartic acid derivative is a compound 3 shown as the following formula (VIII)
When the selected compound is cytarabine structural analogue P1, the obtained product is cytarabine structural analogue P2;
when the selected compound is cytarabine structural analogue P3, the resulting product is cytarabine structural analogue P4.
In a preferred embodiment, the compound is selected from: aspartic acid derivatives: the molar ratio of 1-propyl phosphoric anhydride is 1: (1.2-1.5): (2.0-2.5).
In a preferred technical scheme, the temperature rise is natural temperature rise.
In the preferred technical scheme, the room temperature reaction time is 1-2 hours.
In the preferable technical scheme, petroleum ether/ethyl acetate with the volume ratio of 20/1-1/1 is adopted for column chromatography.
In the preferred technical scheme, the dosage of Pd/C is 2-10% of the mass of the selected compound.
In the preferred technical scheme, the hydrogen is 0.05-0.1 Mpa.
In a preferred technical scheme, the post-treatment comprises the following steps: and (3) allowing the second reaction solution to pass through a kieselguhr pad to collect first filtrate, eluting the kieselguhr pad with methanol to collect second filtrate, combining the first filtrate and the second filtrate to obtain filtrate, concentrating the filtrate, and stirring and filtering with methyl tert-butyl ether to obtain a product.
In a preferred embodiment, the concentration is carried out under reduced pressure, most preferably under reduced pressure at 40 ℃.
In the invention, the room temperature is 20-30 ℃.
In a third aspect of the invention, there is provided the use of a cytarabine structural analogue in the manufacture of a medicament for the treatment of leukaemia.
Furthermore, the invention also provides application of the cytarabine structural analogue in preparing an oral medicament for treating leukemia.
Compared with the prior art, the invention has the following beneficial technical effects:
the cytarabine structural analogues P1-P4 synthesized for the first time can inhibit human leukemia HL-60 cells, have better inhibition effect than cytarabine hydrochloride under low concentration, and are expected to be used as novel anti-leukemia drugs.
Particularly, compared with cytarabine, the cytarabine structural analogue P4 has stronger inhibition capacity on the proliferation of leukemia cells and stronger cell penetrating capacity, the concentration of the medicament entering the cells and the concentration of an active metabolite cytarabine triphosphate generated in the cells are higher, and the bioavailability is higher; the cytarabine is transformed into a parent drug cytarabine in cells, so that the blood concentration of target cells in vivo is remarkably improved, and toxic and side effects and drug resistance caused by large-dose medication can be avoided; obviously prolongs the half-life period of the cytarabine, maintains effective blood concentration for a longer time, and can be orally taken, thereby avoiding the inconvenience caused by injection medication. Therefore, the cytarabine structural analogue P4 completely overcomes the defects of high polarity, poor membrane permeability, easy metabolic inactivation in vivo, short half-life period and the like of cytarabine, provides possibility for oral administration, and fills the technical blank that no new medicine is available in the market at home.
The preparation method of the cytarabine structural analogue is simple and easy to operate, and is expected to be used for industrial production.
Drawings
FIG. 1 is the HNMR spectrum of the compound obtained in example 1, which shows that the structure is shown as formula (II) and is marked as cytarabine structural analogue P1.
FIG. 2 is a graph showing the comparison of the concentrations of intracellular drug and metabolite obtained by incubating different drugs to be tested with human leukemia cell HL60 for different periods of time in example 8.
Detailed Description
Embodiments of the present invention will be described in detail below with reference to the accompanying drawings and specific examples. It should be understood that these examples are for illustrative purposes only and are not to be construed as limiting the scope of the present invention.
Those skilled in the art can use conventional methods, for example, according to the techniques or conditions described in the literature in the field or according to the conditions suggested by the suppliers in the product specifications.
The various instruments, raw materials and reagents not specifically described in the following examples, those not noted in the manufacturers, are all conventional products commercially available. The particular materials used and their sources set forth in the following examples are illustrative only and not intended to be limiting of the invention, as materials identical or similar in type, quality, nature or function to the tissues, cells, reagents and instruments described below may be used in the practice of the invention.
Description of materials and sources:
cytarabine, CAS: 147-94-4, available from Haohnhong biomedical science and technology, Inc., Shanghai.
Cytarabine hydrochloride, CAS: 69-74-9, available from Haohnhong biomedical science and technology, Inc., Shanghai.
Compound 3, having the structure shown in formula (VIII), CAS: 4779-31-1, available from Shanghai Haohnhong biomedical science and technology, Inc.
Compound 4, having the structure shown in formula (VII), is available from Wuhanxi Rui pharmaceutical science and technology, Inc.
1-Propylphosphoric anhydride (50% ethyl acetate solution) available from Shanghai Bidi pharmaceutical science, Inc.
Human leukemia cell HL-60, purchased from Wuhan Pronoch Life technologies, Inc.
PBMC cells, peripheral blood mononuclear cells, were isolated from rat blood by Ficoll lymph isolate (sigma).
Sprague-Dawley rats, purchased from Spibefu (Beijing) Biotechnology Ltd, and assigned quality certificate number SYXK (Ee) 2016-0057 for experimental animals.
Example 1 Synthesis of Cytarabine structural analog P1
The synthetic route is shown as the following formula:
the method comprises the following steps: cytarabine (Compound 1, 5.0g, 20.56mmol) was neutralizedCompound 2(10.72g, 30.84mmol, 1.5eq.) is dissolved in anhydrous THF (tetrahydrofuran, 50mL), N2The temperature is reduced to-78 ℃ under protection, 1-methylimidazole (4.39g, 53.46mmol, 2.6eq.) is slowly dropped, and then the mixture is stirred at-78 ℃ for 2 hours and then naturally heated to room temperature (20 ℃) for reaction for 12 hours. Concentrating the reaction solution at 40 ℃ under reduced pressure, adding DCM (dichloromethane) for dilution, washing with dilute hydrochloric acid (0.5mol/L), water and saturated sodium chloride solution in sequence, combining organic phases, drying over anhydrous sodium sulfate, concentrating at 40 ℃ under reduced pressure, and purifying by column chromatography (DCM/MeOH is 20/1-10/1, V/V, MeOH is methanol) to obtain a white powdery compound.1H-NMR(400MHz,CD3OD): δ 7.76(d, J ═ 4.4Hz, 1H), 7.37 to 7.33(m, 2H), 6.23(d, J ═ 4.0Hz, 1H), 5.78(d, J ═ 7.6Hz, 1H), 4.40 to 4.23(m, 2H), 4.07 to 4.06(m, 1H), 4.05 to 3.96(m, 4H), 1.52 to 1.40(m, 1H), 1.38 to 1.33(m, 7H), 0.91 to 0.87(m, 6H). The HNMR spectrum is shown in FIG. 1. The structure of the cytosine arabinoside analogue is analyzed and determined to be shown as a formula (II) and is marked as a cytarabine structural analogue P1.
Example 2 Synthesis of Cytarabine structural analog P2
The synthetic route is shown as the following formula:
the method comprises the following steps: compound P1(3.0g, 5.41mmol) and compound 3(2.32g, 6.49mmol, 1.2eq.) were dissolved in anhydrous DCM (tetrahydrofuran, 50mL), N2Cooling to 0 deg.C under protection, and slowly adding 1-propyl phosphoric anhydride (50% ethyl acetate solution) (6.88g, wherein, 1-propyl phosphoric anhydride T3P10.82 mmol, 2.0eq.), and then naturally warmed up to room temperature (20 ℃) for reaction for 1 hour. Saturated NaHCO is used for reaction liquid3The solution is quenched, the aqueous phase is extracted with DCM (dichloromethane, 50mL × 2), the organic phases are combined and dried over anhydrous sodium sulfate, concentrated under reduced pressure at 40 ℃, and purified by column chromatography (PE/EA ═ 20/1-1/1, PE is petroleum ether, EA is ethyl acetate) to obtain intermediate P1 a. Intermediate P1a was dissolved in methanol (50mL), Pd/C (0.3g) was added, nitrogen was substituted 3 times, and hydrogen (0.1MPa) was introduced for reaction. After completion of the reaction monitored by TLC (thin layer chromatography), the resulting reaction solution was passed through celiteCollecting the first filtrate with a soil pad, rinsing the diatomaceous earth pad with a small amount of methanol to collect the second filtrate, mixing the filtrates, concentrating at 40 deg.C under reduced pressure, and vacuum filtering with MTBE (methyl tert-butyl ether) under stirring to obtain white powder. LCMS: [ M +1 ]]+And (4) theoretical calculation: 670.24, actually measuring: 670.20.1H-NMR (400MHz, DMSO-d): δ 10.48(s,1H), 8.84(d, J ═ 4.0Hz, 1H), 7.92(s, 1H), 7.37 to 7.23(m, 5H), 6.12(d, J ═ 4.0Hz, 1H), 5.87(d, J ═ 7.6Hz, 1H), 5.11(brs, 2H), 4.40 to 4.23(m, 2H), 4.18(s, 1H), 4.07 to 3.93(m, 6H), 3.81 to 3.66(m, 4H), 2.79(d, J ═ 7.6Hz,2H), 1.40 to 1.33(m, 7H), 0.94 to 0.88(m, 6H). Therefore, the structure is determined as shown in the formula (III) and is marked as a cytarabine structural analogue P2.
Example 3 Synthesis of Cytarabine structural analog P3
The synthetic route is shown as the following formula:
the method comprises the following steps: cytarabine (compound 1, 5.0g, 20.56mmol) and compound 4(16.16g, 30.84mmol, 1.5eq.) were dissolved in anhydrous THF (tetrahydrofuran, 50mL), N2The temperature is reduced to-78 ℃ under protection, 1-methylimidazole (4.39g, 53.46mmol, 2.6eq.) is slowly dropped, and then the mixture is stirred at-78 ℃ for 2 hours and then naturally heated to room temperature (20 ℃) for reaction for 12 hours. Concentrating the reaction solution at 40 ℃ under reduced pressure, adding DCM (dichloromethane) for dilution, washing with dilute hydrochloric acid (0.5mol/L), water and saturated sodium chloride solution in sequence, combining organic phases, drying with anhydrous sodium sulfate, concentrating at 40 ℃ under reduced pressure, and purifying by column chromatography (DCM/MeOH: 20/1-10/1, V/V) to obtain a white powdery compound. LCMS: [ M +1 ]]+And (4) theoretical calculation: 731.46, actually measuring: 731.50.1H-NMR (400MHz, DMSO-d): δ 9.13(d, J ═ 4.0Hz, 1H), 8.79(brs, 1H), 5.89(d, J ═ 7.6Hz, 1H), 5.87(d, J ═ 4.4Hz, 1H), 4.40 to 4.27(m, 2H), 4.23 to 4.06(m, 8H), 3.58(brs, 2H), 1.87 to 1.77(m, 2H), 1.71 to 1.33(m, 39H), 0.98 to 0.88(m, 6H), and the structure thereof is determined as shown in formula (iv)And is marked as cytarabine structural analogue P3.
Example 4 Synthesis of Cytarabine structural analog P4
The synthetic route is shown as the following formula:
compound P3(3.0g, 4.10mmol) and compound 3(1.76g, 4.93mmol, 1.2eq.) were dissolved in anhydrous DCM (tetrahydrofuran, 50mL), N2The temperature is reduced to 0 ℃ under protection, 1-propyl phosphoric anhydride (50 percent ethyl acetate solution) (5.21g, 8.20mmol and 2.0eq. of 1-propyl phosphoric anhydride) is slowly dropped, and then the temperature is naturally raised to room temperature (20 ℃) for reaction for 1 hour. Saturated NaHCO is used for reaction liquid3The solution is quenched, the aqueous phase is extracted with DCM (dichloromethane, 50mL × 2), the organic phases are combined and dried over anhydrous sodium sulfate, concentrated under reduced pressure at 40 ℃, and purified by column chromatography (PE/EA ═ 20/1-1/1, PE is petroleum ether, EA is ethyl acetate) to obtain intermediate P3 a. Intermediate P3a was dissolved in methanol (50mL), Pd/C (0.3g) was added, the mixture was purged with nitrogen 3 times, and then reacted with hydrogen (0.1 MPa). After TLC (thin layer chromatography) monitoring reaction is completed, the obtained reaction liquid passes through a kieselguhr pad to collect a first filtrate, a small amount of methanol is used for leaching the kieselguhr pad to collect a second filtrate, the filtrates obtained by combining the first filtrate and the second filtrate are subjected to reduced pressure concentration at 40 ℃, and are stirred and filtered by MTBE (methyl tert-butyl ether) to obtain a white powdery compound. LCMS: [ M +1 ]]+And (4) theoretical calculation: 846.49, actually measuring: 846.50.1H-NMR (400MHz, DMSO-d): δ 10.48(s,1H), 9.13(d, J ═ 4.0Hz, 1H), 7.92(s, 1H), 5.89(d, J ═ 4.4Hz, 1H), 5.78(d, J ═ 4.0Hz, 1H), 5.11(brs, 2H), 4.40 to 4.27(m, 2H), 4.23 to 4.06(m, 8H), 3.81 to 3.66(m, 6H), 2.79(d, J ═ 7.6Hz,2H), 1.87 to 1.77(m, 2H), 1.71 to 1.33(m, 39H), 0.98 to 0.88(m, 6H). The structure of the derivative is determined by analysis as shown in the formula (V) and is marked as cytarabine structural analogue P4.
Example 5 inhibition of proliferation of human leukemia cells HL-60 by Cytarabine analogs P1-P4
Test compounds: cytarabine hydrochloride and cytarabine analogs P1-P4 prepared in examples 1-4.
Cell culture: placing human leukemia cell line HL-60 in RPMI-1640 culture solution containing 10% fetal calf serum, and adding 5% volume fraction of CO at 37 deg.C2Carrying out subculture in a saturated humidity incubator at regular intervals, and taking cells in a logarithmic growth phase as cells for subsequent experiments.
Preparing a medicine mother solution: the test compound was dissolved in DMSO (dimethyl sulfoxide) to prepare a mother solution having a concentration of 100mmol/L, and the mother solution was stored for use. The experiment was performed by dilution with DMSO to the desired concentration.
And (3) determination of inhibition rate: taking HL-60 cells in logarithmic growth phase, counting the cells to obtain the cell density of 5 multiplied by 104one/mL of the cell suspension was inoculated into a 24-well plate, and 2mL (10 cells) of the cell suspension was added to each well5One/hole). Placing a 24-pore plate in CO with the volume fraction of 5% at 37 DEG C2The cells were incubated in a saturated humidity incubator for 24 hours, and the culture medium was discarded, and 100. mu.L of the culture medium containing the test compound at a concentration of 1.5625. mu. mol/L was added to each well. Control wells were also provided, and 100. mu.L of the culture medium was added to the control wells without the test compound. Each set was provided with 3 multiple wells. Placing a 24-pore plate in CO with the volume fraction of 5% at 37 DEG C2Culturing in a saturated humidity incubator for 72 hours, taking out the 24-well plate, taking out the cells from the well, adding trypan blue in equal proportion, and mixing uniformly. The number of cells in the control well and the dosing well was counted separately using a hemocytometer. The growth inhibition rate was calculated as follows:
growth inhibition (%) was (1-number of drug-added wells/number of control wells) × 100%
The experiments were divided into 5 groups: the first group is a cytarabine structural analogue P1 group, the second group is a cytarabine structural analogue P2 group, the third group is a cytarabine structural analogue P3 group, the fourth group is a cytarabine structural analogue P4 group, and the fifth group is a cytarabine hydrochloride group. The cell proliferation inhibition rates were measured as: 18%, 12%, 14%, 56%, 10%. It can be found that: at the lower concentration, the inhibition effect of the cytarabine structural analogues P1-P4 on the proliferation growth of human leukemia cells HL60 is stronger than that of cytarabine hydrochloride.
Example 6 inhibition of proliferation of human leukemia cells HL-60 by Cytarabine structural analog P1
Test compounds: cytarabine hydrochloride, a cytarabine structural analog P1 prepared in example 1.
Cell culture: placing human leukemia cell line HL-60 in RPMI-1640 culture solution containing 10% fetal calf serum, and adding 5% volume fraction of CO at 37 deg.C2Carrying out subculture in a saturated humidity incubator at regular intervals, and taking cells in a logarithmic growth phase as cells for subsequent experiments.
Preparing a medicine mother solution: the test compound was dissolved in DMSO (dimethyl sulfoxide) to prepare a mother solution having a concentration of 100mmol/L, and the mother solution was stored for use. The experiment was performed by dilution with DMSO to the desired concentration.
And (3) determination of inhibition rate: taking HL-60 cells in logarithmic growth phase, counting the cells to obtain the cell density of 5 multiplied by 104one/mL of the cell suspension was inoculated into a 24-well plate, and 2mL (10 cells) of the cell suspension was added to each well5One/hole). Placing a 24-pore plate in CO with the volume fraction of 5% at 37 DEG C2Incubate in a saturated humidity incubator for 24h, discard the medium, add 100. mu.L of the corresponding medium containing different concentrations of test compound to each well, set 5 concentration gradients (25. mu. mol/L, 12.5. mu. mol/L, 6.25. mu. mol/L, 3.125. mu. mol/L, 1.5625. mu. mol/L) for each test compound, and set 3 multiple wells for each concentration. Control wells were also provided, and 100. mu.L of the culture medium was added to the control wells without the test compound. Control wells were set with 3 replicates. Placing a 24-pore plate in CO with the volume fraction of 5% at 37 DEG C2Culturing in a saturated humidity incubator for 72 hours, taking out the 24-well plate, taking out the cells from the well, adding trypan blue in equal proportion, and mixing uniformly. The number of cells in the control well and the dosing well was counted separately using a hemocytometer. The growth inhibition rate was calculated as follows:
growth inhibition (%) was (1-number of drug-added wells/number of control wells) × 100%
The experiments were divided into cytarabine structural analogue P1 group and cytarabine hydrochloride group. The results of measurement of the HL-60 cell proliferation inhibition rate of each group are shown in the following table 1:
TABLE 1 measurement of HL-60 cell proliferation inhibition ratio of each test compound group
P1 | Cytarabine hydrochloride | |
1.5625μmol/L | 18% | 10% |
3.125μmol/L | 30% | 21% |
6.25μmol/L | 50% | 30% |
12.5μmol/ |
60% | 40% |
25μmol/L | 64% | 56% |
As can be seen from the results in Table 1, the cytarabine structural analogue P1 has an inhibitory effect on HL60 cells at different gradient concentrations. This means that: like cytarabine hydrochloride, cytarabine structural analogue P1 can inhibit proliferation of human leukemia cell HL 60. In addition, at each of the same concentrations, cytarabine structural analogue P1 inhibited the growth of HL60 cells more than cytarabine hydrochloride, showing that: the cytarabine structural analogue P1 has stronger inhibiting effect on HL60 cell proliferation than cytarabine hydrochloride.
Example 7 inhibition of proliferation of human leukemia cells HL-60 by Cytarabine structural analog P4
Test compounds: cytarabine hydrochloride, cytarabine structural analog P4 prepared in example 4.
Cell culture: placing human leukemia cell line HL-60 in RPMI-1640 culture solution containing 10% fetal calf serum, and adding 5% volume fraction of CO at 37 deg.C2Carrying out subculture in a saturated humidity incubator at regular intervals, and taking cells in a logarithmic growth phase as cells for subsequent experiments.
Preparing a medicine mother solution: the test compound was dissolved in DMSO (dimethyl sulfoxide) to prepare a mother solution having a concentration of 100mmol/L, and the mother solution was stored for use. The experiment was performed by dilution with DMSO to the desired concentration.
And (3) determination of inhibition rate: taking HL-60 cells in logarithmic growth phase, counting the cells to obtain the cell density of 5 multiplied by 104one/mL of the cell suspension was inoculated into a 24-well plate, and 2mL (10 cells) of the cell suspension was added to each well5One/hole). Placing a 24-pore plate in CO with the volume fraction of 5% at 37 DEG C2Incubate in a saturated humidity incubator for 24h, discard the medium, add 100. mu.L of the corresponding medium containing different concentrations of test compound to each well, set 5 concentration gradients (25. mu. mol/L, 12.5. mu. mol/L, 6.25. mu. mol/L, 3.125. mu. mol/L, 1.5625. mu. mol/L) for each test compound, and set 3 multiple wells for each concentration. Control wells were also provided, and 100. mu.L of the culture medium was added to the control wells without the test compound. Control wells were set with 3 replicates. Placing a 24-pore plate in CO with the volume fraction of 5% at 37 DEG C2Culturing in a saturated humidity incubator for 72 hours, taking out the 24-well plate, taking out the cells from the well, adding trypan blue in equal proportion, and mixing uniformly. The number of cells in the control well and the dosing well was counted separately using a hemocytometer. The growth inhibition rate was calculated as follows:
growth inhibition (%) was (1-number of drug-added wells/number of control wells) × 100%
The experiments were divided into 3 groups: cytarabine hydrochloride, cytarabine analog P4, and cytarabine hydrochloride. The results of measurement of the HL-60 cell proliferation inhibition rate of each group are shown in the following table 2:
TABLE 2 measurement of HL-60 cell proliferation inhibition ratio of each test compound group
Cytarabine | P4 | Cytarabine hydrochloride | |
1.5625μmol/ |
20% | 56% | 10% |
3.125μmol/L | 34% | 73% | 21% |
6.25μmol/L | 52% | 86% | 30% |
12.5μmol/L | 66% | 90% | 40% |
25μmol/L | 75% | 96% | 56% |
According to the results of Table 2:
(1) under different gradient concentrations, each test compound has inhibitory effect on HL60 cells. This means that: like cytarabine and cytarabine hydrochloride, cytarabine structural analogue P4 can inhibit the proliferation and growth of human leukemia cell HL 60.
(2) At each same concentration, the inhibition rate of the cytarabine structural analogue P4 on the growth of HL60 cells is the highest and is obviously higher than that of the cytarabine group and the cytarabine hydrochloride group. When the concentration is 1.5625 mu mol/L, the inhibition rate of the cytarabine structural analogue P4 on the growth of HL60 cells is 56 percent, and the inhibition rates of cytarabine and cytarabine hydrochloride on the growth of HL60 cells are 20 percent and 10 percent respectively; when the concentration is 25 mu mol/L, the inhibition rate of the cytarabine structural analogue P4 on the growth of HL60 cells is up to 96%, and the inhibition rates of cytarabine and cytarabine hydrochloride on the growth of HL60 cells are 75% and 56% respectively. It can be seen that cytarabine structural analogue P4 has a much stronger inhibitory effect on HL60 cells at each concentration than cytarabine and cytarabine hydrochloride.
Example 8 drug concentrations of Cytarabine structural analogs incubated in HL-60 cells for various times
Taking HL-60 cells in logarithmic growth phase, counting the cells to obtain the cell density of 5 multiplied by 104one/mL of the cell suspension was inoculated into a 24-well plate, and 2mL (10 cells) of the cell suspension was added to each well5One/hole). Placing a 24-pore plate in CO with the volume fraction of 5% at 37 DEG C2Culturing in a saturated humidity incubator for 24h, discarding the culture solution, adding 100 μ L of culture solution containing 100 μmol/L of the drug to be tested into each well, wherein the drug to be tested is cytarabine and the cytarabine prepared in example 4Cytidine structural analog P4. Each group is provided with 3 multiple holes and is placed at 37 ℃ and 5% CO2And (5) continuing culturing in a saturated humidity incubator. After incubation for various periods of time (0.5 hours, 1 hour, 3 hours, 6 hours), the concentrations of the parent drug (cytarabine, designated Ara-C in the figure; or, cytarabine structural analogue P4, designated BX20-1-004 in the figure) and the corresponding active metabolite cytarabine triphosphate (designated Ara-CTP (Ara-C) and Ara-CTP (004) in the figure) were tested in HL-60 cells, respectively. The concentration profile is shown in figure 2.
As can be seen from fig. 2:
(1) with the prolonging of the incubation time, the concentrations of the original drug and the corresponding active metabolite in the HL-60 cells are increased, and when the incubation time is 3 hours or more, the concentration of the active metabolite cytarabine triphosphate in the HL-60 cells exceeds the original drug concentration. This means that cytarabine and the cytarabine structural analogue P4 both entered HL-60 cells and were converted into active metabolites inside the cells.
(2) The intracellular concentration of cytarabine structural analogue P4 was significantly higher than that of cytarabine for the same incubation time, indicating that cytarabine structural analogue P4 had a greater ability to penetrate the cell membrane into the cell than cytarabine.
(3) The concentration of cytarabine triphosphate, an active metabolite in cells treated with cytarabine structural analogue P4, was much higher compared to the concentration of cytarabine triphosphate, an active metabolite in cells treated with cytarabine for the same incubation time. This suggests that: the cytarabine structural analog P4 prepared in example 4 was able to produce higher concentrations of active metabolites than cytarabine, thereby exerting stronger anti-leukemic cell proliferative activity. This indicates that the bioavailability of cytarabine structural analog P4 prepared in example 4 was significantly higher than that of cytarabine.
Example 9 in vivo oral Single dose pharmacokinetic Studies in rats
8 Sprague-Dawley rats were divided into two groups: the cytarabine and cytarabine structural analogue groups, each group comprising 4 rats, were orally administered with a single dose of a cytarabine structural analogue P4 solution (physiological saline solution, drug concentration 10mg/mL) and a cytarabine solution (physiological saline solution, drug concentration 10mg/mL), respectively, at the following doses: the concentration of cytosine arabinoside is 10mg/Kg rat.
Determination by liquid chromatography-Mass Spectrometry (HPLC-MS/MS): (1) (ii) cytarabine concentration in plasma and PBMC cells following oral administration of cytarabine; (2) the concentration of the proto-drug (cytarabine structural analogue P4) in plasma and PBMC cells following oral administration of cytarabine structural analogue P4; (3) the metabolite cytarabine concentration in plasma and PBMC cells following oral administration of cytarabine structural analogue P4. The results are shown in table 3 below as the pharmacokinetic parameters (n-4) of the proto-drug and the metabolite cytarabine in plasma and PBMC cells after a single oral administration in rats. Cytarabine structural analogue P4 is shown as BX20-1-004 in Table 3.
Table 3: pharmacokinetic parameters of proto-drug and metabolite cytarabine in plasma and PBMC cells after oral single administration in rats
In Table 3, AUC is the area under the curve when drug is administered, and means the area enclosed by the curve of plasma concentration with respect to the time axis, and is expressed in ng.h/mL. The parameter is an important index for evaluating the absorption degree of the drug and reflects the exposure characteristic of the drug in vivo. CmaxThe peak concentration refers to the highest blood concentration after administration. This parameter is an important index reflecting the rate and extent of absorption of the drug in vivo. t is tmaxThe peak reaching time refers to the time required to reach the peak concentration of the drug after administration. The parameter reflects the speed of the drug entering the body, and the peak reaching time is short when the absorption speed is high. t is t1/2Is the terminal elimination half-life, which refers to the time required for the terminal phase blood concentration to decrease by half. This parameter visually reflects the rate of elimination of the drug from the body.
As can be seen from table 3:
(1) the AUC of the cytarabine structural analogue P4 (BX 20-1-004 in the table) entering PBMC after the cytarabine structural analogue P4 is administered is obviously higher than that of the cytarabine entering PBMC after the cytarabine is administered, which indicates that the cytarabine structural analogue P4 has better cell penetrability than the cytarabine.
(2) The AUC of cytarabine in plasma after administration of the cytarabine structural analogue P4 was significantly lower than the AUC of cytarabine in plasma after administration of cytarabine, which means that less inactive uracil cytarabine was subsequently produced in plasma and the bioavailability of the cytarabine structural analogue P4 was higher.
(3) The peak cytarabine concentration in PBMC cells after administration of cytarabine structural analogue P4 (986ng/mL) was more than twice the peak cytarabine concentration in PBMC cells after administration of cytarabine (436 ng/mL). The cytarabine structural analogue P4 can be converted into the parent cytarabine in cells, the blood concentration of target cells in vivo is obviously improved, and the bioavailability is higher.
(4) The time to peak of cytarabine in PBMC cells after administration of cytarabine structural analogue P4 (26.1h) was significantly higher than the time to peak of cytarabine in PBMC cells after administration of cytarabine (0.83 h). This means that: the cytarabine structural analogue P4 significantly prolonged the intracellular time of cytarabine.
(5) The half-life of cytarabine in PBMC cells after administration of cytarabine structural analogue P4 (25.5h) was significantly higher than the time to peak of cytarabine in PBMC cells after administration of cytarabine (1.02 h). This means that: the cytosine arabinoside structural analogue P4 for oral administration has longer half-life, good stability of cytosine arabinoside in PBMC cells, and can maintain effective blood concentration for a longer time.
In conclusion, the cytarabine structural analogues P1-P4 synthesized for the first time can inhibit human leukemia HL-60 cells, have better inhibition effect than cytarabine hydrochloride under low concentration, and are expected to be used as novel anti-leukemia drugs.
Particularly, compared with cytarabine, the cytarabine structural analogue P4 has stronger proliferation inhibition capacity on leukemia cells HL60 and stronger cell penetrating capacity, the concentration of the medicine entering the cells and the concentration of an active metabolite cytarabine triphosphate generated in the cells are higher, and the bioavailability is higher; can be converted into the parent drug cytarabine in cells, obviously improves the blood concentration of target cells in vivo, and can avoid toxic and side effects and drug resistance caused by large-dose medication; can obviously prolong the half-life period of the cytarabine, maintain the effective blood concentration for a longer time, can be orally taken, and can avoid the inconvenience caused by injection. Therefore, the cytarabine structural analogue P4 completely overcomes the defects of high polarity, poor membrane permeability, easy metabolic inactivation in vivo, short half-life period and the like of cytarabine, provides possibility for oral administration, and fills the technical blank that no new medicine is available in the market at home.
The preparation method of the cytarabine structural analogue is simple and easy to operate, and is expected to be used for industrial production.
It should be noted that the above-mentioned embodiments are only preferred embodiments of the present invention, and the present invention is not limited thereto, and although the present invention has been described in detail with reference to the foregoing embodiments, it will be apparent to those skilled in the art that modifications and equivalents can be made in the technical solutions described in the foregoing embodiments, or equivalents thereof. Any modification, equivalent replacement, or improvement made within the spirit and principle of the present invention should be included in the protection scope of the present invention. Although the embodiments of the present invention have been described with reference to the accompanying drawings, it is not intended to limit the scope of the present invention, and it should be understood by those skilled in the art that various modifications and variations can be made without inventive efforts by those skilled in the art based on the technical solution of the present invention.
Claims (10)
2. The cytarabine structural analog of claim 1, which is any one of the following cytarabine structural analogs P1-P4:
cytarabine structural analogue P1 represented by the following formula (ii):
cytarabine structural analogue P2 represented by the following formula (iii):
cytarabine structural analogue P3 represented by the following formula (iv):
cytarabine structural analog P4 represented by the following formula (V):
3. the process for producing a cytarabine structural analogue according to claim 1 or 2, comprising the steps of:
dissolving cytarabine and phosphoryl chloride derivatives in anhydrous tetrahydrofuran, N2Cooling to-70-78 ℃ under protection, slowly dripping 1-methylimidazole, stirring at-70-78 ℃, heating to room temperature for reaction, and after the reaction is finished, carrying out post-treatment and purification on reaction liquid to obtain a product; wherein,
when the phosphoryl chloride derivative is a compound 2 shown as the following formula (VI), the obtained product is a cytarabine structure analogue P1;
when the phosphoryl chloride derivative is a compound 4 shown as the following formula (VII), the obtained product is a cytarabine structure analogue P3;
4. the method for producing a cytarabine structural analog of claim 3, wherein cytarabine: phosphorus oxychloride derivatives: the molar ratio of 1-methylimidazole is 1: (1.5-2.0): (2.0-3.0).
5. The method for preparing a cytarabine structural analog of claim 3, wherein the post-treatment purification comprises: concentrating the reaction solution, adding dichloromethane for dilution, washing with dilute hydrochloric acid, water and saturated sodium chloride solution successively, combining organic phases, drying, concentrating, and purifying by column chromatography to obtain the product.
6. The process for producing a cytarabine structural analogue according to claim 1 or 2, comprising the steps of:
dissolving the selected compound and aspartic acid derivative in anhydrous tetrahydrofuran, N2Cooling to-5-0 deg.C under protection, slowly dripping 1-propyl phosphoric anhydride, heating to room temperature for reaction, and reacting to obtain the first reaction solution3Quenching the solution, extracting the water phase by using dichloromethane, combining the organic phases, drying, concentrating, and purifying by column chromatography to obtain an intermediate; dissolving the intermediate in methanol, adding Pd/C, introducing hydrogen for reaction, monitoring by thin-layer chromatography, and performing aftertreatment on the obtained second reaction liquid to obtain a product; wherein,
the aspartic acid derivative is a compound 3 shown as the following formula (VIII)
When the selected compound is cytarabine structural analogue P1, the obtained product is cytarabine structural analogue P2;
when the selected compound is cytarabine structural analogue P3, the resulting product is cytarabine structural analogue P4.
7. The method of making a cytarabine structural analog of claim 6, wherein the compound selected is: aspartic acid derivatives: the molar ratio of 1-propyl phosphoric anhydride is 1: (1.2-1.5): (2.0-2.5).
8. The method of preparing a cytarabine structural analog of claim 6, wherein the post-treatment comprises: and (3) allowing the second reaction solution to pass through a kieselguhr pad to collect first filtrate, eluting the kieselguhr pad with methanol to collect second filtrate, combining the first filtrate and the second filtrate to obtain filtrate, concentrating the filtrate, and stirring and filtering with methyl tert-butyl ether to obtain a product.
9. Use of a cytarabine structural analogue according to claim 1 or 2 in the manufacture of a medicament for the treatment of leukemia.
10. Use of a cytarabine structural analogue according to claim 1 or 2 in the manufacture of an oral medicament for the treatment of leukemia.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011427716.1A CN112409431B (en) | 2020-12-07 | 2020-12-07 | Cytarabine structural analogue, and preparation method and application thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011427716.1A CN112409431B (en) | 2020-12-07 | 2020-12-07 | Cytarabine structural analogue, and preparation method and application thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN112409431A true CN112409431A (en) | 2021-02-26 |
CN112409431B CN112409431B (en) | 2023-04-21 |
Family
ID=74774953
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202011427716.1A Active CN112409431B (en) | 2020-12-07 | 2020-12-07 | Cytarabine structural analogue, and preparation method and application thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN112409431B (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112892891A (en) * | 2021-03-03 | 2021-06-04 | 武汉伯瑞恒医药科技有限公司 | Centrifugal device for extracting anti-leukemia active molecules and intermediates |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101787064A (en) * | 2009-01-23 | 2010-07-28 | 高峰 | Cytarabine prodrug derivatives and purposes thereof in resisting cancers and tumors |
CN101812105A (en) * | 2009-02-25 | 2010-08-25 | 沈阳药科大学 | Cytarabine 5'-O-amino-acid ester, salts thereof and preparation method thereof |
CN102115485A (en) * | 2009-12-30 | 2011-07-06 | 济南圣鲁金药物技术开发有限公司 | Prodrug based on cytosine arabinoside structure, and synthesis method and application thereof |
US20130210757A1 (en) * | 2011-01-03 | 2013-08-15 | Nanjing Molecular Research, Inc. | Double-liver-targeting phosphoramidate and phosphonoamidate prodrugs |
CN104119385A (en) * | 2014-07-24 | 2014-10-29 | 廖国超 | Phosphate prodrug of nucleoside analog and application of phosphate prodrug |
CN104903339A (en) * | 2012-11-16 | 2015-09-09 | 卡迪夫大学学院顾问有限公司 | Process for preparing nucleoside prodrugs |
CN106459127A (en) * | 2014-05-28 | 2017-02-22 | 艾登尼克斯药业有限公司 | Nucleoside derivatives for the treatment of cancer |
CN108289905A (en) * | 2015-12-03 | 2018-07-17 | 拜欧赛特有限公司 | A acyl cytosine arabinoside conjugate for cancer therapy |
CN110590862A (en) * | 2019-11-01 | 2019-12-20 | 南京师范大学 | Cytarabine 4-N amino acid derivative and preparation method and application thereof |
-
2020
- 2020-12-07 CN CN202011427716.1A patent/CN112409431B/en active Active
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101787064A (en) * | 2009-01-23 | 2010-07-28 | 高峰 | Cytarabine prodrug derivatives and purposes thereof in resisting cancers and tumors |
CN101812105A (en) * | 2009-02-25 | 2010-08-25 | 沈阳药科大学 | Cytarabine 5'-O-amino-acid ester, salts thereof and preparation method thereof |
CN102115485A (en) * | 2009-12-30 | 2011-07-06 | 济南圣鲁金药物技术开发有限公司 | Prodrug based on cytosine arabinoside structure, and synthesis method and application thereof |
US20130210757A1 (en) * | 2011-01-03 | 2013-08-15 | Nanjing Molecular Research, Inc. | Double-liver-targeting phosphoramidate and phosphonoamidate prodrugs |
CN104903339A (en) * | 2012-11-16 | 2015-09-09 | 卡迪夫大学学院顾问有限公司 | Process for preparing nucleoside prodrugs |
CN106459127A (en) * | 2014-05-28 | 2017-02-22 | 艾登尼克斯药业有限公司 | Nucleoside derivatives for the treatment of cancer |
CN104119385A (en) * | 2014-07-24 | 2014-10-29 | 廖国超 | Phosphate prodrug of nucleoside analog and application of phosphate prodrug |
CN108289905A (en) * | 2015-12-03 | 2018-07-17 | 拜欧赛特有限公司 | A acyl cytosine arabinoside conjugate for cancer therapy |
CN110590862A (en) * | 2019-11-01 | 2019-12-20 | 南京师范大学 | Cytarabine 4-N amino acid derivative and preparation method and application thereof |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112892891A (en) * | 2021-03-03 | 2021-06-04 | 武汉伯瑞恒医药科技有限公司 | Centrifugal device for extracting anti-leukemia active molecules and intermediates |
CN112892891B (en) * | 2021-03-03 | 2022-12-06 | 武汉伯瑞恒医药科技有限公司 | Centrifugal device for extracting anti-leukemia active molecules and intermediates |
Also Published As
Publication number | Publication date |
---|---|
CN112409431B (en) | 2023-04-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN110054652B (en) | Jatrorrhizine platinum (II) complex and synthesis method and application thereof | |
CN102702298B (en) | Glycyrrhetinic acid derivative and preparation method and medical application thereof | |
CN113234116A (en) | Tripterine derivative, preparation method and medical application thereof | |
CN112409431B (en) | Cytarabine structural analogue, and preparation method and application thereof | |
CN111423438B (en) | Eudistomins Y derivatives with antitumor activity and preparation method and application thereof | |
CN104693256B (en) | The pharmaceutical applications of gemcitabine derivative, the composition containing the derivative and the derivative | |
CN107286220B (en) | 1,2, 4-triazole coupled dihydromyricetin derivative and preparation method and application thereof | |
CN102627685A (en) | Nitric oxide-donating glutathione compound, preparation method and medical purpose thereof | |
CN108129543B (en) | Oleanolic acid derivative and preparation method and application thereof | |
CN107698639B (en) | N-formate hypoxia-activated prodrug of gemcitabine phosphate and application thereof | |
CN103204898A (en) | Anticancer compound and application thereof | |
CN105503947A (en) | Preparation method of phosphonate derivative containing amino acid fragments and antineoplastic application | |
CN102746212B (en) | Beta-elemene indole derivative, preparation and application thereof | |
CN102115485A (en) | Prodrug based on cytosine arabinoside structure, and synthesis method and application thereof | |
RU2418795C2 (en) | Dioxolane derivatives for cancer treatment | |
CN101891772B (en) | Method for preparing disodium 5'-ribonucleotide | |
CN105732758B (en) | Cholic acid α aminophosphonate ester derivatives and its synthetic method | |
AU2011274194B2 (en) | Phenyl nitrone compounds containing stilbene segment and use thereof | |
CN103319485B (en) | 6-(beta-alkylnaphthy)mercaptopurine compound, and synthesis method and application thereof | |
CN113336816B (en) | Cytidine compounds and anti-tumor application thereof | |
CN111499568B (en) | Preparation and application of cyanoacrylate derivative containing pyridine bi-4-mercaptoaryl unit | |
CN102690313B (en) | Cholic acid-naphthoylimine compounds and application thereof | |
CN110713464B (en) | Aryl 1,2,4-triazole nucleoside compound and preparation method and application thereof | |
CN109846818B (en) | Injection of antineoplastic medicine with ubenimex structure and preparation method thereof | |
CN103613626B (en) | A kind of adenosine cyclophosphate compound and meglumine adenosine cyclophosphate medicine composition thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Structural analogues of cytarabine and their preparation methods and applications Granted publication date: 20230421 Pledgee: Bank of China Limited Wuhan Hanyang sub branch Pledgor: Wuhan Bereheng Pharmaceutical Technology Co.,Ltd. Registration number: Y2024980022569 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right |